A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification.

Saved in:
Bibliographic Details
Title: A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification.
Authors: Tarpgaard LS; Department of Oncology, Odense University Hospital, Odense, Denmark. line.tarpgaard@rsyd.dk., Qvortrup C; Department of Oncology, Odense University Hospital, Odense, Denmark. camilla.qvortrup@rsyd.dk., Nygård SB; Faculty of Health and Medical Sciences, Department of Veterinary Disease Biology, University of Copenhagen, Frederiksberg, Denmark. Sune.Boris.Nygaard@regionh.dk.; Department of Pathology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. Sune.Boris.Nygaard@regionh.dk., Nielsen SL; Faculty of Health and Medical Sciences, Department of Veterinary Disease Biology, University of Copenhagen, Frederiksberg, Denmark. siln@sund.ku.dk., Andersen DR; Department of Oncology, Odense University Hospital, Odense, Denmark. diana.riise.andersen@rsyd.dk., Jensen NF; Faculty of Health and Medical Sciences, Department of Veterinary Disease Biology, University of Copenhagen, Frederiksberg, Denmark. tfm434@alumni.ku.dk., Stenvang J; Faculty of Health and Medical Sciences, Department of Veterinary Disease Biology, University of Copenhagen, Frederiksberg, Denmark. stenvang@sund.ku.dk., Detlefsen S; Department of Pathology, Odense University Hospital, Odense, Denmark. sonke.detlefsen@rsyd.dk., Brünner N; Faculty of Health and Medical Sciences, Department of Veterinary Disease Biology, University of Copenhagen, Frederiksberg, Denmark. nbr@sund.ku.dk., Pfeiffer P; Department of Oncology, Odense University Hospital, Odense, Denmark. per.pfeiffer@rsyd.dk.
Source: BMC cancer [BMC Cancer] 2016 Feb 11; Vol. 16, pp. 91. Date of Electronic Publication: 2016 Feb 11.
Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1471-2407
DOI:10.1186/s12885-016-2124-5